
Loading, please wait...

Loading, please wait...

Managing antiplatelet therapy during spinal reconstruction presents a delicate clinical balancing act. For decades, surgical teams routinely discontinued antiplatelet medications before major spinal operations to prevent catastrophic hemorrhagic complications. However, emerging clinical evidence suggests that perioperative aspirin continuation may not elevate operative morbidity in selected minimally invasive approaches. Minimally invasive anterior-to-psoas (MIS-ATP) lumbar fusion has gained widespread adoption due to reduced tissue trauma and rapid recovery profiles. Consequently, spine surgeons increasingly question whether blanket drug discontinuation remains necessary for these less disruptive techniques.
Patients presenting for lumbar fusion frequently carry substantial cardiovascular comorbidities, including ischemic heart disease, prior percutaneous coronary interventions, and peripheral vascular occlusive disease. Therefore, interrupting chronic antiplatelet therapy exposes these high-risk individuals to life-threatening rebound thrombotic events. A recent propensity-matched cohort study published in Spine directly examined this critical dilemma. Specifically, researchers evaluated whether maintaining low-dose acetylsalicylic acid throughout the surgical period compromises intraoperative hemostasis or postoperative recovery. Their findings provide robust empirical support for refining perioperative antithrombotic protocols in minimally invasive spinal arthrodesis.
Spine surgery historically carries a heightened dread of epidural hematoma and retroperitoneal bleeding. Even small volumes of uncontained hemorrhage within the spinal canal can produce irreversible neurological injury or paralysis. As a result, surgeons traditionally mandated a strict five- to seven-day preoperative drug washout. Nevertheless, stopping aspirin completely abolishes platelet inhibition and triggers a dangerous rebound prothrombotic state. Platelet turnover and heightened thromboxane production during drug withdrawal dramatically elevate the incidence of acute coronary syndromes and perioperative stroke.
In addition, cardiac guidelines strongly advocate maintaining antiplatelet protection in patients with drug-eluting coronary stents. Discontinuing aspirin in these vulnerable cohorts increases cardiac mortality substantially more than surgical bleeding events typically do. However, orthopaedic and neurological spine literature has historically lagged behind other surgical disciplines regarding antiplatelet continuation. Minimally invasive approaches like MIS-ATP alter the surgical equation considerably. Because the anterior-to-psoas trajectory utilizes natural anatomical corridors, hemorrhagic risk profiles differ markedly from traditional open posterior decompression. Therefore, re-evaluating surgical risks through procedure-specific evidence has become essential for modern clinical practice.
To eliminate confounding factors inherent to observational data, researchers conducted a meticulous propensity score-matched study at an academic medical center. They reviewed 455 consecutive adult patients who underwent MIS-ATP lumbar fusion accompanied by supplemental percutaneous posterior fixation between 2014 and 2020. Among these participants, 134 individuals (29.5%) continued low-dose aspirin throughout the surgical episode. Conversely, 321 individuals (70.5%) discontinued therapy preoperatively. Baseline comparisons initially revealed significant disparities between groups, as aspirin users were older and possessed higher rates of systemic cardiovascular disease.
Consequently, investigators implemented 1:1 nearest-neighbor propensity score matching to generate balanced, comparable cohorts. The matching algorithm rigorously adjusted for chronological age, biological sex, body mass index, and race. Furthermore, the model balanced crucial systemic medical comorbidities, including essential hypertension, diabetes mellitus, coronary artery disease, and chronic kidney disease. Investigators also accounted for active smoking, alcohol consumption, baseline laboratory profiles, and fused spinal segments. This robust statistical methodology successfully yielded 86 perfectly balanced patient pairs for definitive comparative analysis.
The propensity-matched outcomes revealed that maintaining low-dose aspirin did not worsen intraoperative or immediate postoperative metrics. Specifically, mean operative duration was nearly identical between the continuation group and the discontinuation group (224.7 ± 97.9 minutes versus 228.6 ± 90.1 minutes; P = 0.79). Similarly, intraoperative estimated blood loss showed no statistically significant difference across the matched cohorts (244.4 ± 456.0 mL versus 278.4 ± 418.7 mL; P = 0.62). These objective values demonstrate that active platelet inhibition does not impede surgical pacing or foster uncontrollable capillary oozing during tissue dissection.
Moreover, postoperative laboratory measurements and recovery markers corroborated the operative findings. Day-1 postoperative hemoglobin concentrations remained remarkably consistent between cohorts (10.88 ± 1.49 g/dL in continuers versus 11.08 ± 1.76 g/dL in discontinuers; P = 0.41). In addition, overall allogeneic blood transfusion rates demonstrated clinical parity (18.6% versus 15.1%; P = 0.54). Most importantly, life-threatening retroperitoneal hematoma occurred at an identical incidence of 1.2% in both treatment arms (P = 1.00). Total hospital length of stay also did not differ significantly between groups (4.83 ± 3.72 days versus 4.20 ± 2.49 days; P = 0.22), confirming that aspirin continuation did not delay discharge.
Historically, surgical dogma demanded that patients cease taking aspirin at least seven days before elective spinal procedures. Proponents argued that a complete week allows newly synthesized, fully functional platelets to enter the bloodstream and achieve baseline hemostatic competence. However, the study directly tested this assumption through a targeted subanalysis. The research team compared the 134 patients who maintained aspirin therapy directly against a matched subset of individuals who held their medication for seven days or longer preoperatively.
Notably, this secondary comparison of 15 well-matched pairs demonstrated zero clinical advantage for withholding the drug. Patients who endured prolonged medication washout experienced similar blood loss, equivalent transfusion requirements, and indistinguishable operative durations compared to patients who continued therapy uninterrupted. Furthermore, unnecessary medication interruption exposed patients to prolonged intervals without cardioprotective platelet suppression. Consequently, this targeted subanalysis strongly challenges the necessity of arbitrary multi-day washout windows in minimally invasive retroperitoneal surgery. Surgical teams can safely discard routine drug cessation protocols that lack empirical justification, thereby protecting patients from preventable cardiovascular morbidity without compromising surgical safety.
These findings carry profound practical implications for spine surgeons, neurosurgeons, and perioperative anesthesiologists. The anterior-to-psoas corridor traverses retroperitoneal fatty spaces rather than tearing extensively through vascular posterior paraspinal musculature. Because surgeons perform disc space preparation, interbody spacer insertion, and anterior stabilization through narrow operative corridors, meticulous direct visualization enables rapid mechanical and thermal hemostasis. As a result, modest antiplatelet-induced platelet impairment does not translate into clinically dangerous hemorrhage under modern illumination and visualization systems.
Nevertheless, clinicians must avoid applying these conclusions indiscriminately across all spinal operations. Complex multi-level osteotomies, extensive open deformity corrections, and high-risk intradural procedures may carry different bleeding risks that warrant tailored antiplatelet cessation. Therefore, surgical teams should adopt an individualized, approach-specific protocol rather than enforcing rigid, blanket mandates. Close interdisciplinary coordination between spine surgeons, cardiologists, and anesthesiologists ensures that cardiovascular risk stratification drives antiplatelet planning. By moving toward nuanced risk assessment, clinicians can preserve essential cardiac protection while maintaining impeccable surgical safety during minimally invasive lumbar arthrodesis.
The propensity-matched study demonstrated that continuing low-dose aspirin during MIS-ATP lumbar fusion did not increase estimated blood loss, operative time, transfusion rates, or hospital stay. Furthermore, rates of retroperitoneal hematoma remained identical at 1.2% between cohorts, confirming the safety of uninterrupted antiplatelet therapy in this setting.
No, the study subanalysis revealed no hemostatic or clinical benefit from withholding aspirin for seven days or longer before surgery. Patients who discontinued aspirin experienced operative durations, blood loss volumes, and transfusion rates comparable to continuers, while needlessly exposing themselves to increased rebound thrombotic cardiovascular risks.
The MIS-ATP approach relies on an anatomical retroperitoneal corridor that avoids extensive disruption of vascular posterior paraspinal muscles. Furthermore, minimally invasive tubular retractors, precise visualization, and targeted bipolar electrocautery allow surgeons to achieve rapid, reliable local hemostasis despite mild platelet inhibition from continued low-dose aspirin therapy.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A propensity-matched study shows perioperative aspirin continuation does not increase surgical morbidity or bleeding in minimally invasive anterior-to-psoas (MIS-ATP) lumbar fusion. The findings challenge routine antiplatelet discontinuation, advocating approach-specific perioperative management.
Today

A randomized crossover trial evaluated fifth-year medical students interacting with an AI standardized patient versus a human standardized patient. The study revealed key differences in Mini-CEX scores, active engagement, and interview dynamics.
Today

A comparative evaluation of INNO-LiPA, Cobas 4800, and Amplicor highlights significant assay-dependent variation in high-risk HPV detection, emphasizing the clinical distinction between analytical sensitivity and screening specificity.
Today

A Canadian nutrition study reveals that higher diet costs predict lower dietary energy density and higher fruit intake, but also increase sodium and processed meat consumption.
Today

Idiopathic spinal cord herniation is a rare pathology presenting with progressive thoracic myelopathy. Early MRI identification and meticulous microsurgical reduction with dual bolstered dural defect repair prevent irreversible neurological deterioration.
Today

A novel smartphone-assisted biosensor utilizing molecularly imprinted polymers and catalytic nanozymes offers antibody-free, enzyme-free urinary microalbumin testing, enabling rapid, low-cost point-of-care screening for early chronic kidney disease.
Today